Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pemigatinib is used in adults to treat bile duct cancer that has spread to other···【more】
Release date：2024-08-14Recommended：208
Pemigatinib is an effective treatment for advanced or metastatic cholangiocarcin···【more】
Release date：2024-08-14Recommended：188
Pemigatinib leads to constitutive activation of FGFR by activating FGFR amplific···【more】
Release date：2024-08-14Recommended：195
Venetoclax is a targeted anti-cancer drug used to treat certain types of blood c···【more】
Release date：2024-08-13Recommended：226
Venetoclax is a novel oral small molecule drug that targets the BCL-2 protein to···【more】
Release date：2024-08-13Recommended：313
Venetoclax is a small molecule drug that targets BCL-2 and is able to promote no···【more】
Release date：2024-08-13Recommended：218
Venetoclax is an oral anticancer drug targeting BCL-2 that promotes apoptosis of···【more】
Release date：2024-08-13Recommended：179
By binding to BCL-2 protein, venetoclax inhibits the obstruction of apoptosis of···【more】
Release date：2024-08-13Recommended：219
Venetoclax is a small molecule drug approved in combination with azacitidine for···【more】
Release date：2024-08-13Recommended：207
Venetoclax is an oral targeted drug that can effectively inhibit the anti-apopto···【more】
Release date：2024-08-13Recommended：274
Venetoclax is a targeted drug used in the treatment of a variety of hematologic ···【more】
Release date：2024-08-13Recommended：231
Venetoclax is the only approved selective inhibitor of Bcl-2 in the world. By bi···【more】
Release date：2024-08-13Recommended：219
